Maverick Total Disc Replacement in a 'Real World' Patient Population (Maverick)
Maverick Total Disc Replacement in a 'Real World' Patient Population - A Prospective, Multicenter, Observational Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Quebec, Canada, H3G1A4
- Montreal General Hospital
-
-
-
-
-
Bordeaux, France, 33076
- CHU Pellegrin Tripode
-
Clamart, France, 92141
- CH Antoine Béclère - Service de Chirurgie Orthopédique
-
Clichy, France, 92110
- Service de Chirurgie Orthopédique, AP-HP, Hôpital Beaujon
-
Lille Cedex, France, 59037
- Clinique de Neurochirurgie Hôpital Roger Salengro
-
Marseille, France, 13385
- CH La Timone
-
Meulan, France, 78250
- CH de Meulan - Service de Chirurgie Orthopédique
-
Nice, France, 06300
- Service de Neurochirurgie Hôpital Nice
-
Paris, France, 75010
- CH Lariboisière, Service de Neurochirurgie
-
Toulouse, France, 31300
- Clinique du cours Dillon
-
-
-
-
-
Berlin, Germany, 10117
- Charité Berlin - Klinik für Orthopädie
-
Magdeburg, Germany, 39120
- Universitätsklinikum Magdeburg
-
Potsdam, Germany, 14482
- Praxis für Orthopädie und Neurochirurgie Potsdam
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- Degenerative Disc Disease (DDD) defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies
- Foraminal stenosis due to loss of disc height
- Back pain and/or leg pain.
Exclusion criteria:
- Spondylolisthesis at the affected or adjacent level
- Posterior facet joint damage and/or disease at the affected level, including facet osteoarthritis, pars fracture and prior laminectomy
- Obesity
- Osteoporosis
- Metallic allergy to cobalt-chromium-molybdenum alloys
- Psychosis
- Infection
- Spinal canal stenosis
- Overlying thoracolumbar kyphosis
- Systemic infection or infection at the site of surgery
- Osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated
- Diseases of bone metabolism
- Pregnancy
- Signs of local inflammation
- Fever or Leukocytosis
- Grossly distorted anatomy caused by congenital abnormalities
- Any other medical or surgical condition which would preclude the potential benefit of spinal implant surgery, such as the presence of congenital abnormalities, elevation of sedimentation rate unexplained by other diseases, elevation of white blood count (WBC), or a marked left shift in the WBC differential count (this also includes: spinal active oncology pathology; not healed fracture at treated or adjacent level)
- Any case where the implants or components selected would be too large or too small to achieve a successful result
- Any patient in which implant utilization would interfere with anatomical structures or expected physiological performance
- Any patient unwilling to follow postoperative instructions.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
lumbar spinal arthroplasty + Maverick™
Patients requiring total disc replacement
|
All patients will be subjected to a lumbar spinal arthroplasty.
The anterior lumbar spine is approached through either a transperitoneal or retroperitoneal exposure.
A complete anterior discectomy is performed and the Maverick™ Artificial Disc System is inserted to replace the damaged lumbar intervertebral disc.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduction of Disability at 6 Months Versus Baseline Using the Oswestry Disability Index (ODI)
Time Frame: 6 months
|
The Oswestry Disability Index (ODI) derives from the Oswestry Low Back Pain Questionnaire, it is used to measure disability for low back pain.
The index is scored from 0 to 100; 0 meaning 'no disability' and 100 meaning 'maximum disability'.
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relief of Back Pain at 6 Months Versus Baseline Using the Back Pain Intensity Score Assessed on a 10 cm Visual Analogue Scale (VAS)
Time Frame: 6 months
|
Back Pain was documented in a Visual Analogue Scale where the patients marked the location on the 10-centimeter line corresponding to the amount of pain they experienced. 0 = no pain, 10 = worst possible pain |
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Maverick Global Registry
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.